W.L. Gore & Associates, Inc., Appellant/cross-Appellee v. Garlock, Inc., Appellee/cross-Appellant

721 F.2d 1540, 220 U.S.P.Q. (BNA) 303, 1983 U.S. App. LEXIS 13701
CourtCourt of Appeals for the Federal Circuit
DecidedNovember 14, 1983
Docket83-613, 83-614
StatusPublished
Cited by364 cases

This text of 721 F.2d 1540 (W.L. Gore & Associates, Inc., Appellant/cross-Appellee v. Garlock, Inc., Appellee/cross-Appellant) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
W.L. Gore & Associates, Inc., Appellant/cross-Appellee v. Garlock, Inc., Appellee/cross-Appellant, 721 F.2d 1540, 220 U.S.P.Q. (BNA) 303, 1983 U.S. App. LEXIS 13701 (Fed. Cir. 1983).

Opinions

MARKEY, Chief Judge.

Appeal from a judgment of the District Court for the Northern District of Ohio holding U.S. Patents 3,953,566 (’566) and 4,187,390 (’390) invalid. We affirm in part, reverse in part, and remand for a determination of the infringement issue.

Background

Tape of unsintered polytetrafluorethy-lene (PTFE) (known by the trademark [1545]*1545TEFLON of E.I. du Pont de Nemours, Inc.) had been stretched in small increments. W.L. Gore & Associates, Inc. (Gore), assign-ee of the patents in suit, experienced a tape breakage problem in the operation of its “401” tape stretching machine. Dr. Robert Gore, Vice President of Gore, developed the invention disclosed and claimed in the ’566 and ’390 patents in the course of his effort to solve that problem. The 401 machine was disclosed and claimed in Gore’s U.S. Patent 3,664,915 (’915) and was the invention of Wilbert L. Gore, Dr. Gore’s father. PTFE tape had been sold as thread seal tape, i.e., tape used to keep pipe joints from leaking. The ’915 patent, the application for which was filed on October 3, 1969, makes no reference to stretch rate, at 10% per second or otherwise, or to matrix tensile strength in excess of 7,300 psi.

Dr. Gore experimented with heating and stretching of highly crystalline PTFE rods. Despite slow, careful stretching, the rods broke when stretched a relatively small amount. Conventional wisdom in the art taught that breakage could be avoided only by slowing the stretch rate or by decreasing the crystallinity. In late October, 1969, Dr. Gore discovered, contrary to that teaching, that stretching the rods as fast as possible enabled him to stretch them to more than ten times their original length with no breakage. Further, though the rod was thus greatly lengthened, its diameter remained virtually unchanged throughout its length. The rapid stretching also transformed the hard, shiny rods into rods of a soft, flexible material.

Gore developed several PTFE products by rapidly stretching highly crystalline PTFE, including: (1) porous film for filters and laminates; (2) fabric laminates of PTFE film bonded to fabric to produce a remarkable material having the contradictory properties of impermeability to liquid water and permeability to water vapor, the material being used to make “breathable” rainwear and filters; (3) porous yarn for weaving or braiding into other products, like space suits and pump packing; (4) tubes used as replacements for human arteries and veins; and (5) insulation for high performance electric cables.

On May 21, 1970, Gore filed the patent' application that resulted in the patents in suit. The ’566 patent has 24 claims directed to processes for stretching highly crystalline, unsintered, PTFE. The processes, inter alia, include the steps of stretching PTFE at a rate above 10% per second and at a temperature between about 35 °C and the crystalline melt point of PTFE. The ’390 patent has 77 claims directed to various products obtained by processes of the ’566 patent.

It is effectively undisputed that the present inventions filled a long sought yet unfilled need. The United States Army and the research director of a Garlock, Inc. (Garlock) customer had been looking for and following up every remote lead to a waterproof/breathable material for many years.

It is undisputed that the present inventions enjoyed prompt and remarkable commercial success due to their merits and not to advertising or other extraneous causes.

It is undisputed that the inventions provide the most important synthetic material available for use in vascular surgery, hundreds of thousands of persons having received artificial arteries formed of the patented product since 1976, and that the patented products have unique properties useful in other medical procedures, in communications satellites, radar systems, and electrical applications.

It is undisputed that the major sources of PTFE, ICI and du Pont, greeted the patented product as “magical”, “bewitching”, “a remarkable new material”, and one that “differs from other processed forms of Tef-lon”.

It is undisputed that the patented products were met with skepticism and disbelief by at least one scientist who had worked with PTFE at du Pont for many years and who testified as an expert at trial.

It is undisputed that Garlock first produced an accused product in response to a customer’s request for a substitute for the [1546]*1546patented product, that Garlock advertised its accused product as a “new form” of PTFE and as “a versatile new material which provides new orders of performance for consumer, industrial, medical and electrical applications”, and that the customer describes that accused product as “a new dimension in rainproof/breathable fabrics”.

Proceedings

On Nov. 2, 1979, Gore sued Garlock for infringement of process claims 3 and 19 of the '566 patent, and sought injunctive relief, damages, and attorney fees. Garlock counterclaimed on Dec. 18, 1979, for a declaratory judgment of patent invalidity, non-infringement, fraudulent solicitation, and entitlement to attorney fees. On Feb. 7, 1980, Gore filed a second suit for infringement of product claims 14, 18, 36, 43, 67 and 77 of the ’390 patent. In light of a stipulation, the district court consolidated the two suits for trial.

Gore alleged infringement of certain claims by certain products:

[[Image here]]

At trial, Garlock addressed only claims 1, 3,17, and 19 of the ’566 patent and claims 1, 9,12,14,18, 35, 36, 43, 67, and 77 of the ’390 patent. See Appendix to this opinion.

The district court, in a thorough memorandum accompanying its judgment, and in respect of the ’566 patent: (1) found claim 1 anticipated under 35 U.S.C. § 102(a) by Gore’s use of its 401 machine and use by the Budd Company (Budd) of a Cropper machine; (2) declared all claims of the patent invalid under 102(b) because the invention had been in public use and on sale more than one year before Gore’s patent application, as evidenced by Budd’s use of the Cropper machine; (3) held claims 1, 3, 17 and 19 invalid for obviousness under 35 U.S.C. § 103, on the basis of various reference pairings: (a) Japanese patent 13560/67 (Sumitomo) with U.S. patent 3,214,503 (Markwood); (b) U.S. patent 2,776,465 (Smith) with Markwood; or (c) Gore’s ’915 patent with Sumitomo; and (4) held all claims invalid as indefinite under 35 U.S.C. § H2.1

In its opinion respecting the ’390 patent, the district court held: (1) claims 1, 9, 12, 14, 18, 35, 36, 43, 67 and 77 invalid under §§ 102 and 103 in view of Sumitomo and Smith; and (2) all claims invalid as indefinite under § 112.

[1547]*1547The court found that Gore did not commit fraud before the Patent and Trademark Office (PTO), denied Garlock’s request for attorney fees, and refrained from deciding the infringement issue.

Issues

Did the district court err in: (1) its holdings of invalidity under §§ 102(a), 102(b), 103 and 112; (2) its finding that Gore did not commit fraud on the PTO; or (3) denying attorney fees.

OPINION

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Nano-Second Technology Co. v. Dynaflex International
944 F. Supp. 2d 855 (C.D. California, 2013)
Delano Farms Co. v. California Table Grape Commission
940 F. Supp. 2d 1229 (E.D. California, 2013)
Mitsubishi Chemical Corp. v. Barr Laboratories, Inc.
718 F. Supp. 2d 382 (S.D. New York, 2010)
American Medical Systems, Inc. v. Laser Peripherals, LLC
712 F. Supp. 2d 885 (D. Minnesota, 2010)
Therasense, Inc. v. Becton, Dickinson and Co.
565 F. Supp. 2d 1088 (N.D. California, 2008)
Tokyo Keiso Co., Ltd. v. SMC Corp.
533 F. Supp. 2d 1047 (C.D. California, 2007)
Advanceme Inc. v. RAPIDPAY, LLC
509 F. Supp. 2d 593 (E.D. Texas, 2007)
SYNVASIVE CORP. v. Stryker Corp.
478 F. Supp. 2d 1193 (E.D. California, 2007)
LP MATTHEWS LLC v. Bath & Body Works, Inc.
458 F. Supp. 2d 198 (D. Delaware, 2006)
McNeil-PPC, Inc. v. Perrigo Co.
443 F. Supp. 2d 492 (S.D. New York, 2006)
Avocent Huntsville Corp. v. Clearcube Technology, Inc.
443 F. Supp. 2d 1284 (N.D. Alabama, 2006)
Boston Scientific Scimed, Inc. v. Cordis Corp.
434 F. Supp. 2d 308 (D. Delaware, 2006)
RH MURPHY CO., INC. v. Illinois Tool Works, Inc.
409 F. Supp. 2d 53 (D. Massachusetts, 2006)
IMX, Inc. v. LENDINGTREE, LLC
405 F. Supp. 2d 479 (D. Delaware, 2005)
Kao Corp. v. Unilever United States, Inc.
334 F. Supp. 2d 527 (D. Delaware, 2004)
IXYS Corp. v. Advanced Power Technology, Inc.
321 F. Supp. 2d 1133 (N.D. California, 2004)
Bristol-Myers Squibb Co. v. Andrx Pharmaceuticals, Inc.
343 F. Supp. 2d 1124 (S.D. Florida, 2004)
Genzyme Corp. v. ATRIUM MEDICAL CORP.
315 F. Supp. 2d 552 (D. Delaware, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
721 F.2d 1540, 220 U.S.P.Q. (BNA) 303, 1983 U.S. App. LEXIS 13701, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wl-gore-associates-inc-appellantcross-appellee-v-garlock-inc-cafc-1983.